the FCC approving Paramount's $8 billion merger with Sky Dance Media. Joining us right now is Matt Bellan. He's uh Puck's founding partner.Uh the deal looks like it's in the books, Matt. And so the question really, we can go back and and litigate everything that's happened, but what comes next. What are the sort of the first pieces of things that we're you think we're going to start to see as a result of all this.Yeah. Can you believe we're still talking about this deal. It hasn't closed yet.Um, I think wha ...

Congratulations to the winners of the Chainlink Chromion Hackathon.3K+ builders submitted 400+ projects across DeFi, RWAs, & cross-chain applications.See who took home prizes & how they're using Chainlink to power the next wave of onchain apps ↓https://t.co/1TAuWMjOzh ...

CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE® (zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specifically indicated to treat dep ...

Centene chief executive officer Sarah London on Friday July 25, 2025 said the company is ... More "disappointed by our second quarter results, but we have a clear understanding of the trends that have impacted our performance, and are working with urgency and focus to restore our earnings trajectory." In this photo, London speaks during the Forbes Healthcare Summit in New York, US, on Tuesday, Dec. 5, 2023. Photographer: Michael Nagle/Bloomberg© 2023 Bloomberg Finance LPHealth insurer Centene reported a $25 ...

The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizations FRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO ...

The likelihood that AI may soon make lots of workers redundant is well known. What is much less discussed is the hope that the tech can set the world on a path of explosive growth. That would have profound consequences https://t.co/62zveH50Bt ...

UNDERSTANDING $ION TOKEN BURNS - The @ice_blockchain ecosystem is built to be deflationary... But it's not that simple https://t.co/am4MsPZDnV ...

New Phygital Infrastructure Empowers U.S. Universities to Expand Globally Through AI-powered Hybrid Classrooms CUPERTINO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Ambow Education Holding Ltd. (NYSE American: AMBO), a U.S.-based innovator of AI-powered phygital (physical + digital) solutions for education, corporate collaboration and live events, today announced the launch of its HybriU Global Learning Network (HGLN), a two-pronged initiative designed to help U.S. universities scale international enrollme ...

2025年，家居行业发展迎来了全新的技术浪潮，有家居企业掌舵者称之为从传统到未来的转折点。 在大趋势之下，智能、出海是大家居行业内最有共识的两个确定性方向，后者是市场的扩容与裂变，而智能方向则是大家居企业面向未来生存与发展的必 由之路。 2025中国建博会（广州） 7月8日-11日，2025中国建博会（广州）盛大开幕。作为大家居建装行业全球第一展，中国建博会（广州）是大家居品牌展示实力、最新发展动向，以及 企业间沟通交流、共同探索行业未来的重要平台。从中国建博会（广州）现场可以清晰看出大家居行业的进化动向。 本届展会展览面积30万平方米，参展企业近2000家，高端会议活动逾70场，共有来自145个国家和地区的205621名有商业价值的高质量专业观众到会，与 去年基本持平，其中海外观众8602人，同比增长47.22%，继续保持大家居建装行业展览领先地位。 2025中国建博会（广州） 展会期间，与未来趋势关联最为紧密的智能家居馆场面火爆，成为最瞩目的焦点。华为鸿蒙智家、海尔、海信、博世等科技企业巨头，照明、整装等领域 内的智能家居产业链上下游、以及智能家居集成服务商纷纷齐聚本届展会的智能家居馆，各家品牌的新产品、 ...

Core Insights - The U.S. Keytruda market is projected to decline from an estimated size of USD 17.87 billion in 2024 at a CAGR of 3.12% from 2025 to 2033 due to challenges such as patent expiration and biosimilar competition [1][2] - Keytruda, developed by Merck & Co., is a significant player in oncology, particularly for lung cancer, melanoma, and urothelial carcinoma, but faces pricing pressures despite rising cancer incidence [2][3] - Merck is addressing access barriers through a new subcutaneous formulation expected in 2025, which aims to enhance treatment convenience and maintain market share [3][4] Market Dynamics - The market is supported by Keytruda's use in both monotherapy and combination regimens, with expanding indications in neoadjuvant and adjuvant settings [3] - Clinical trials, such as KEYNOTE-689, have demonstrated improved survival outcomes, contributing to increased adoption [3] - The incidence of cancer in the U.S. is estimated at 2 million new cases in 2024, indicating a growing patient population despite market challenges [2] Competitive Landscape - The market faces competition from emerging biosimilars following Keytruda's expected patent expiration in 2028, which could impact market dynamics [1][2] - Innovations such as biomarker-driven approaches and new combination therapies are being explored to enhance Keytruda's effectiveness [4] - Merck is also investigating new applications for Keytruda, including colorectal cancer, to mitigate risks associated with market competition [4] Future Outlook - The U.S. remains the leading market for Keytruda due to its advanced healthcare infrastructure, but future growth will be influenced by competitive and economic pressures [4] - Ongoing clinical evaluations and the introduction of new formulations are expected to play a crucial role in sustaining market activity despite anticipated declines [1][3]